FGP
ACAD icon

Freestone Grove Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Freestone Grove Partners’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.76M Buy
69,393
+22,950
+49% +$505K 0.01% 438
2026
Q1 		$1.03M Buy
+46,443
New +$1.11M 0.01% 467

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Freestone Grove Partners's ACAD Position: Q2 2026 in Review

Freestone Grove Partners increased its Acadia Pharmaceuticals (ACAD) stake by 49% in Q2 2026, buying an estimated $505K and bringing the position to 69,393 shares worth $1.76M. The position accounts for 0.01% of the portfolio, ranked #438.

Freestone Grove Partners first reported a position in ACAD in Q1 2026 and has held it in 2 quarters since. 354 funds tracked by Wall St. Rank hold ACAD as of Q2 2026.

  • Freestone Grove Partners held 69,393 shares of Acadia Pharmaceuticals worth $1.76M as of Q2 2026.
  • Freestone Grove Partners bought 22,950 Acadia Pharmaceuticals shares in Q2 2026, an estimated $505K.
  • Acadia Pharmaceuticals made up 0.01% of Freestone Grove Partners's portfolio in Q2 2026, its #438 holding.
  • Freestone Grove Partners first reported a position in Acadia Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • 354 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q2 2026.

Based on Freestone Grove Partners's 13F filing for Q2 2026, filed 14 Aug 2026.